Filter
832
Filtered Results: 832
Text search:
in
vitro
Featured
Recommendations
100
New Publications
147
Language
Document type
No document type
336
Guidelines
236
Studies & Reports
123
Manuals
70
Fact sheets
26
Strategic & Response Plan
24
Training Material
9
Situation Updates
4
Resource Platforms
3
Brochures
1
Countries / Regions
India
32
Latin America and the Carribbean
26
Germany
23
Russia
23
South Africa
20
Brazil
17
Global
17
Africa
13
Colombia
11
Western and Central Europe
11
Argentina
10
Kenya
9
Peru
9
Ethiopia
8
Zambia
8
Bolivia
8
Paraguay
8
Eastern Europe
7
Rwanda
6
Namibia
6
Ukraine
6
Venezuela
6
Burkina Faso
5
Uganda
5
Tanzania
5
Indonesia
5
El Salvador
5
Nigeria
4
Senegal
4
Cameroon
4
West and Central Africa
4
Middle East and North Africa
4
Sierra Leone
3
Congo, Democratic Republic of
3
Mali
3
Niger
3
Nepal
3
Benin
3
Eswatini/ Swaziland
3
Ecuador
3
Lesotho
3
Myanmar / Burma
3
East and Southern Africa
3
Eastern Europe and Central Asia
3
Congo-Brazzaville
3
France
3
Spain
3
Guinea
2
Liberia
2
Côte d’Ivoire / Ivory Coast
2
Haiti
2
Philippines
2
Syria
2
Chad
2
Bangladesh
2
Malawi
2
Angola
2
Madagascar
2
Chile
2
Yemen
2
Asia
2
Tajikistan
2
Kazakhstan
2
Guinea-Bissau
1
Morocco
1
USA
1
Saudi Arabia
1
Ghana
1
Togo
1
Zimbabwe
1
Somalia
1
South Sudan
1
Iraq
1
Jordan
1
Afghanistan
1
Lebanon
1
Turkey
1
Egypt
1
Thailand
1
Gambia
1
Mauritania
1
Mozambique
1
Sudan
1
Dominican Republic
1
North Macedonia
1
Serbia
1
Cuba
1
Burundi
1
Honduras
1
Libya
1
Guatemala
1
Mexico
1
Nicaragua
1
South–East Asia Region
1
Luxembourg
1
Albania
1
Djibouti
1
Armenia
1
Mongolia
1
Southern Africa
1
Laos
1
Canada
1
Qatar
1
Uzbekistan
1
Kyrgyzstan
1
Georgia
1
North America
1
Belgium
1
Tunisia
1
Belarus
1
Israel
1
Authors & Publishers
Publication Years
Category
Countries
245
Clinical Guidelines
153
Pharmacy & Technologies
47
Public Health
24
Women & Child Health
23
Key Resources
18
Capacity Building
1
Toolboxes
COVID-19
157
TB
108
HIV
91
AMR
55
NTDs
44
Pharmacy
32
Ebola
29
Rapid Response
28
Zika
16
Caregiver
16
Planetary Health
15
Refugee
13
Mental Health
12
Polio
6
NCDs
6
Global Health Education
4
Conflict
3
Specific Hazards
3
Cholera
2
Natural Hazards
2
Disability
1
Social Ethics
1
BMC Res Notes (2016) 9:182 DOI 10.1186/s13104-016-1993-7
Report on ILGA-Europe/COC fact-finding mission
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Division of Tuberculosis Elimination
Accessed: 08.10.2019
WHO recommends that pre-exposure prophylaxis (PrEP) be offered as an additional prevention choice for HIV-negative individuals at substantial risk of HIV infection as part of combination prevention approaches.
HIV drug resistance has been rarely reported among PrEP users who tested HIV positive <... randomized controlled trials or open-label studies. However, PrEP-selected HIV drug resistance could potentially negatively impact the effectiveness of treatment options among PrEP users who acquire HIV, since there is a potential for overlapping resistance profiles between antiretroviral drugs used for both PrEP and first-line antiretroviral therapy.
The pre-clinical pipeline shows more innovation and diversity, with 252 agents being developed to treat WHO priority pathogens.
However, these products are in the very early stages of development and still need to be proven effective and safe. Th...
Of the 50 antibiotics in the pipeline, 32 target WHO priority pathogens but the majority have only limited benefits when compared to existing antibiotics. Two of these are active against the multi-drug resistant Gram-negative bacteria, which are spr...
Antimicrobial resistance (AMR) is an important public health concern shared by developed and developing countries. In developing countries the burden of infectious diseases is greater and exacerbated by limited access to, and availability and afford...
This guideline provides advice in regards to applications for Marketing Authorisations for antimicrobial veterinary medicinal products (VMPs) on the data required and the methodology to be used for performing an assessment of the risk to public heal...
Confronted with the important issue of patient safety, in 2002 the Fifty-fifth World Health Assembly adopted a resolution urging countries to pay the closest possible attention to the problem and to strengthen safety and monitoring systems. ... May 2004, the Fifty-seventh World Health Assembly approved the creation of an international alliance as a global initiative to improve patient safety. The World Alliance for Patient Safety was launched in October 2004 and currently has its place in the WHO Patient Safety programme included in the Information, Evidence and Research Cluster.
Internationally, there is a growing concern over antimicro-bial resistance (AMR) which is currently estimated to ac-count for more than 700,000 deaths per year worldwide. If no appropriate measures are taken to halt its pro-gress, AMR will cost approximately 10 million lives andabout US$100 trillion...
WHO estimates that in 2015, 257 million people were living with chronic hepatitis B virus (HBV) infection worldwide, and that 900 000 died from HBV infection, mostly through the development of cirrhosis and hepatocellular carcinoma. Worldwide, the m...
Sepsis remains a leading cause of mortality and morbidity, especially during the first five days of life and in low and middle-income countries (LMIC) [1]. Hospital infection also remains a major cause of mortality ... children despite progress encountered in the last decades.
Interim guidance, 6 October 2021
Direct detection of SARS-CoV-2 viral proteins (antigens) in nasal swabs and other respiratory secretions using lateral flow immunoassays (also known as rapid diagnostic tests, RDTs) offers a faster and less expensiv...
The global pandemic has highlighted fragility in international supply chains and the dependency of many African countries on imported personal protective equipment (PPE). Market pressures have also increased prices for imported supplies and put addi...
2nd edition, June 2021
WHO operational handbook on tuberculosis Module 5: Management of tuberculosis in children and adolescents
recommended
The practical guidance in the operational handbook aims to inform the development or revision of national policies and related implementation guidance on the management of TB in children and adolesc...
During the COVID-19 health crisis, community pharmacists had an enhanced role in supporting health-care systems that were overburdened by managing seriously ill patients. This study was undertaken to determine the patterns of community supply of ant...
This report presents an analysis of antibacterial agents in preclinical (third annual review) and clinical (fifth annual review) development. The analysis covers traditional (direct-acting small molecules) and non-traditional antibacterial agents ... development worldwide. It evaluates to what extent the present pipeline addresses infections caused by WHO Priority Pathogens, Mycobacterium tuberculosis and Clostridioides difficile. The report also provides an assessment of the traditional agents with respect to whether they meet a set of predefined criteria for innovation, namely absence of known cross-resistance, new target, mode of action and/or class. It also includes an overview of the agents that obtained authorization since 1 July 2017.
